[go: up one dir, main page]

CA2398603A1 - Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants - Google Patents

Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA2398603A1
CA2398603A1 CA002398603A CA2398603A CA2398603A1 CA 2398603 A1 CA2398603 A1 CA 2398603A1 CA 002398603 A CA002398603 A CA 002398603A CA 2398603 A CA2398603 A CA 2398603A CA 2398603 A1 CA2398603 A1 CA 2398603A1
Authority
CA
Canada
Prior art keywords
polypeptide
fgf
leu
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002398603A
Other languages
English (en)
Inventor
Roland Luethy
Robert Yang
Sidney Suggs
Ildiko Sarosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2398603A1 publication Critical patent/CA2398603A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des polypeptides du facteur 23 de croissance de fibroblastes et des molécules d'acides nucléiques les codant. L'invention concerne aussi des agents liants sélectifs, des vecteurs, des cellules hôtes et des procédés pour produire des polypeptides FGF-23. L'invention concerne aussi des compositions pharmaceutiques et des procédés pour le diagnostic, le traitement, l'amélioration et/ou la prévention de maladies, troubles et états associés aux polypeptides FGF-23.
CA002398603A 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants Abandoned CA2398603A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18244200P 2000-02-15 2000-02-15
US60/182,442 2000-02-15
US19890300P 2000-04-20 2000-04-20
US60/198,903 2000-04-20
US74858101A 2001-02-15 2001-02-15
PCT/US2001/004778 WO2001061007A2 (fr) 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
US09/784,581 2001-02-15

Publications (1)

Publication Number Publication Date
CA2398603A1 true CA2398603A1 (fr) 2001-08-23

Family

ID=27391551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002398603A Abandoned CA2398603A1 (fr) 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants

Country Status (6)

Country Link
EP (1) EP1257645A2 (fr)
JP (1) JP2005508131A (fr)
AU (1) AU3976701A (fr)
CA (1) CA2398603A1 (fr)
MX (1) MXPA02007619A (fr)
WO (1) WO2001061007A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066596A2 (fr) * 2000-03-08 2001-09-13 Chiron Corporation Gene humain fgf-23 et produits d'expression genique
JP2003531583A (ja) * 2000-03-08 2003-10-28 カイロン コーポレイション ヒトfgf−23遺伝子および遺伝子発現産物
AU2001273323B2 (en) 2000-07-19 2005-11-10 Advanced Research & Technology Institute Novel fibroblast growth factor (FGF23) and methods for use
US20040082506A1 (en) * 2000-08-11 2004-04-29 Takeyoshi Yamashita Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
AU2002302581A1 (en) * 2001-04-26 2002-11-11 Geneprot, Inc. Human fibroblast growth factor-related compositions
CA2471656C (fr) * 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Anticorp diriges contre le facteur de croissance 23 des fibroblastes
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
SG190592A1 (en) * 2008-04-29 2013-06-28 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2726511B1 (fr) 2011-07-01 2019-08-07 NGM Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
EP2925775B1 (fr) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102724421B1 (ko) 2012-12-27 2024-10-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
CA2951153A1 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procedes et utilisations pour la modulation de l'homeostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EA201791238A1 (ru) 2014-12-04 2018-02-28 Новартис Аг Способы и композиции, в которых используются варианты полипептидов klotho
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 胆汁酸に関係した障害の治療方法
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733222B2 (en) * 1997-11-25 2001-05-10 Genentech Inc. Fibroblast growth factor-19
WO2000060085A1 (fr) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Facteur de croissance 20 des fibroblastes
EP1210418B1 (fr) * 1999-06-02 2010-08-18 Genentech, Inc. Polypeptides secretes et transmembranaires ainsi que les acides nucleiques codant pour ceux-ci
JP2003518944A (ja) * 2000-01-05 2003-06-17 ザイモジェネティクス,インコーポレイティド 新規fgf相同体zfgf12

Also Published As

Publication number Publication date
AU3976701A (en) 2001-08-27
WO2001061007A2 (fr) 2001-08-23
JP2005508131A (ja) 2005-03-31
WO2001061007A3 (fr) 2002-03-14
EP1257645A2 (fr) 2002-11-20
WO2001061007A9 (fr) 2002-04-18
MXPA02007619A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
US20060160181A1 (en) Fibroblast Growth Factor-23 molecules and uses thereof
US7348162B2 (en) Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
CA2398603A1 (fr) Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
US7531321B2 (en) Fibroblast growth factor-like molecules and uses thereof
AU2001241968A1 (en) Chordin-like-2 molecules and uses thereof
EP1266000A1 (fr) Molecules de type chordine 2 et utilisations de celles-ci
CA2481509A1 (fr) Molecules de tyrosine kinase du recepteur her-2 et utilisations associees
WO2002000723A2 (fr) Molecules de recepteur de lymphopoietine de stroma thymique et utilisations de celles-ci
AU2006200916B2 (en) Secreted Epithelial Colon Stromal-1 Polypeptides, Nucleic Acids Encoding the Same and Uses Thereof
US7842784B2 (en) Chordin-like molecules and uses thereof
US20020151695A1 (en) Transforming growth factor-beta-related molecules and uses thereof
US20140273089A1 (en) Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
EP1947182A1 (fr) Molécules 23 à facteur de croissance de fibroblaste et utilisations associées
JP2006238894A (ja) 線維芽細胞成長因子−23分子およびその使用
AU2006200820A1 (en) Fibroblast Growth Factor-23 Molecules and Uses Thereof
AU2005209710A1 (en) Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead